Want to see KR:005250 full AI Analyst Report?
GC Corp. (005250) AI Stock Analysis
Top Page
GC Corp.
(Korea Exchange:005250)
The score is primarily held down by weak financial performance (TTM revenue decline, deeper losses, and rising leverage) and bearish technical signals (price below key moving averages with negative MACD). Valuation provides partial support via the ~3.32% dividend yield, but the negative P/E underscores the current loss-making profile.
GC Corp. (005250) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- KRW 411.06B
- Dividend Yield
- 3.28%
- Average Volume (3M)
- 78.87K
- Price to Earnings (P/E)
- -3.4
- Beta (1Y)
- 0.26
- Revenue Growth
- 9.57%
- EPS Growth
- -203.15%
- Country
- KR
- Employees
- 163
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
GC Corp. Business Overview & Revenue Model
Company Description
GC Corp., formerly known as Green Cross Holdings Corporation, is a South Korean biotechnology company. It provides a range of products including prescription drugs, vaccines, and blood plasma derivatives, and also offers pharmaceutical logistics and...
GC Corp. Financial Statement Overview
Summary
Income statement quality is weak (revenue down sharply in TTM and net losses deepening), and balance sheet risk is rising with higher leverage and negative returns on equity. Cash flow is the main offset: operating cash flow improved and TTM free cash flow turned positive, but it remains modest relative to the debt load.
Income Statement
38NegativeBalance Sheet
44NeutralCash Flow
46Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.49T | 2.45T | 2.20T | 2.06T | 2.08T | 1.84T |
| Gross Profit | 644.83B | 659.59B | 620.36B | 603.58B | 698.34B | 628.54B |
| EBITDA | 157.88B | 142.16B | 212.83B | 66.84B | 180.23B | 201.86B |
| Net Income | -122.14B | -69.51B | 24.03B | -54.14B | 32.82B | 55.27B |
Balance Sheet | ||||||
| Total Assets | 4.18T | 4.07T | 3.67T | 3.74T | 3.59T | 3.50T |
| Cash, Cash Equivalents and Short-Term Investments | 107.82B | 99.28B | 84.10B | 196.11B | 239.98B | 398.39B |
| Total Debt | 1.69T | 1.49T | 1.13T | 1.28T | 1.11T | 1.02T |
| Total Liabilities | 2.44T | 2.30T | 1.82T | 1.86T | 1.63T | 1.59T |
| Stockholders Equity | 868.40B | 900.93B | 994.09B | 980.25B | 1.04T | 1.03T |
Cash Flow | ||||||
| Free Cash Flow | 19.79B | -86.57B | -147.67B | -172.27B | -30.02B | -38.07B |
| Operating Cash Flow | 164.17B | 24.30B | -89.95B | -39.65B | 97.16B | 103.77B |
| Investing Cash Flow | -286.72B | -350.93B | 147.23B | -134.35B | -283.96B | -110.21B |
| Financing Cash Flow | 83.06B | 324.48B | -141.42B | 140.56B | 51.34B | -116.46B |
GC Corp. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:005250, the sentiment is Negative. The current price of 9140.00 is below the 20-day moving average (MA) of 9462.00, below the 50-day MA of 9686.00, and below the 200-day MA of 12122.79, indicating a bearish trend. The MACD of -159.60 indicates Positive momentum. The RSI at 40.08 is Neutral, neither overbought nor oversold. The STOCH value of 19.06 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:005250.
GC Corp. Peers Comparison
Overall Rating
KR:00569070Outperform
KR:95021045Neutral- KR:00525044Neutral
KR:19980043Neutral
KR:30244043Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| KR:005690 | 70Outperform | KRW 563.92B | 12.12 | ― | 0.53% | 51.28% | 124.70% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| KR:950210 | 45Neutral | KRW 241.59B | -2.61 | ― | ― | 84.72% | -480.97% |
| KR:005250 | 44Neutral | KRW 418.50B | -3.40 | ― | 3.28% | 9.57% | -203.15% |
| KR:199800 | 43Neutral | KRW 285.35B | -16.97 | ― | ― | 116.74% | -482.50% |
| KR:302440 | 43Neutral | KRW 2.57T | -30.71 | ― | ― | 23.25% | -58.35% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| KR:005250 | GC Corp. | 9140.00 | -6356.97 | -41.02% | |
| KR:005690 | Pharmicell Co., Ltd | 9400.00 | -8738.31 | -48.18% | |
| KR:064550 | Bioneer Corporation | 6810.00 | -7720.00 | -53.13% | |
| KR:199800 | ToolGen Incorporated | 29200.00 | -25684.21 | -46.80% | |
| KR:302440 | SK bioscience Co.,Ltd. | 32750.00 | -18050.00 | -35.53% | |
| KR:950210 | Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh | 4020.00 | -8280.00 | -67.32% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026